研究单位：[1]Jiangsu Province Centers for Disease Control and Prevention[2]Hubei Provincial Center for Disease Control and Prevention[3]Tongji Hospital[4]CanSino Biologics Inc.[5]Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China[6]Hubei Provincial Center for Disease Control and Prevention,Wuhan,Hubei,China
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China. It has manifest into a global health crisis with escalating confirmed cases and spread across many countries. In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of diseases caused by COVID-19 can be tough for current treatment. This study is a phase I clinical trial. The investigators intent to evaluate the safety, reactogenicity and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) .
